Electrochemotherapy for Desmoid Tumors

Key facts

Sponsor

Istituto Ortopedico Rizzoli

Principal Investigator

Giancarlo Facchini, Medicine and Surgery

IRCCS Istituto Ortopedico Rizzoli

Intervention

Electrochemotherapy with bleomycin(procedure)

Enrollment

30 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2029

Study locations (1)

• IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Desmoid tumor

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07541430
  A Study in Adults With Desmoid Tumors
  Elpiscience (Suzhou) Biopharma, Ltd.
• RECRUITINGPHASE4NCT07176689
  Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
  SpringWorks Therapeutics, Inc.
• ACTIVE NOT RECRUITINGPHASE2NCT07170644
  A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
  SpringWorks Therapeutics, Inc.
• RECRUITINGNCT06945887
  Treatment of Desmoid Fibromatosis With Arterial Embolization
  Istituto Ortopedico Rizzoli
• RECRUITINGNCT07496242
  Immunological Phenotype of Desmoid-fibromatosis-affected Patients.
  Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
• RECRUITINGPHASE2NCT05879146
  Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
  M.D. Anderson Cancer Center
• RECRUITINGNANCT06081400
  Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
  University Hospital, Strasbourg, France
• RECRUITINGNCT06224283
  Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation
  Istituto Ortopedico Rizzoli

See all trials for Desmoid tumor →